Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 6, 2015, Pages

  Di Pauli, Franziska ^a   Höftberger, Romana ^b   Reindl, Markus ^a   Beer, Ronny ^a   Rhomberg, Paul ^a   Schanda, Kathrin ^a   Sato, Douglas ^d   Fujihara, Kazuo ^d   Lassmann, Hans ^c   Schmutzhard, Erich ^a   Berger, Thomas ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Medical University of Vienna   (Austria)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; CORTICOSTEROID; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY; OLIGOCLONAL BAND; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ACUTE RESPIRATORY FAILURE; AGED; ARTICLE; ARTIFICIAL VENTILATION; ASTROCYTE; BLINDNESS; BLOOD; CASE REPORT; CEREBROSPINAL FLUID; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DISEASE COURSE; ENCEPHALOMYELITIS; FULMINANT DEMYELINATING ENCEPHALOMYELITIS; GAIT DISORDER; HUMAN; HUMAN CELL; HUMAN TISSUE; LUMBAR PUNCTURE; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC CHIASM; OPTIC NERVE; PRIORITY JOURNAL; PROGNOSIS; QUADRIPLEGIA; RESPIRATORY FAILURE; SEROCONVERSION; SERUM; VISUAL DISORDER;

EID: 84952909952     PISSN: 23327812     EISSN: None     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000175     Document Type: Article

References (40)

1. Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun 2014;48-49:134-142.
2. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
3. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
4. Popescu BF, Lucchinetti CF. Pathology of demyelinating diseases. Annu Rev Pathol 2012;7:185-217.
5. Kuhlmann T, Lassmann H, Bruck W. Diagnosis of inflammatory demyelination in biopsy specimens: a practical approach. Acta Neuropathol 2008;115:275-287.
6. Berger T, Reindl M. Antibody biomarkers in CNS demyelinating diseases: a long and winding road. Eur J Neurol 2015;22:1162-1168.
7. O'Connor KC, McLaughlin KA, De Jager PL, et al. Selfantigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007;13: 211-217.
8. Probstel AK, Rudolf G, Dornmair K, et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflamm 2015; 12:46.
9. Ketelslegers IA, Van Pelt DE, Bryde S, et al. Anti-MOG antibodies plead against MS diagnosis in an acquired demyelinating syndromes cohort. Mult Scler 2015;21: 1513-1520.
10. Di Pauli F, Mader S, Rostasy K, et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol 2011;138:247-254.
11. McLaughlin KA, Chitnis T, Newcombe J, et al. Agedependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009;183: 4067-4076.
12. Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflamm 2011;8:184.
13. Hoftberger R, Sepulveda M, Armangue T, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 2015;21:866-874.
14. Titulaer MJ, Hoftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014;75:411-428.
15. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010;75:208-216.
16. Krumbholz M, Hofstadt-van Oy U, Angstwurm K, et al. Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. J Neurol 2015;262:1379-1384.
17. Collongues N, Marignier R, Jacob A, et al. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Mult Scler 2013; 20:1086-1094.
18. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
19. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-189.
20. Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013;19:1261-1267.
21. Koelman DL, Mateen FJ. Acute disseminated encephalomyelitis: current controversies in diagnosis and outcome. J Neurol 2015;262:2013-2024.
22. Callen DJ, Shroff MM, Branson HM, et al. MRI in the diagnosis of pediatric multiple sclerosis. Neurology 2009; 72:961-967.
23. Verhey LH, Branson HM, Shroff MM, et al. MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol 2011;10:1065-1073.
24. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
25. Young NP, Weinshenker BG, Parisi JE, et al. Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain 2010; 133:333-348.
26. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79:1273-1277.
27. Reindl M, Rostasy K. MOG antibody-associated diseases. Neurol Neuroimmunol Neuroinflamm 2015;2:e60.
28. Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009;66:833-842.
29. Waters P, Woodhall M, O'Connor KC, et al. MOG cellbased assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2015;2:e89.
30. Rostasy K, Mader S, Schanda K, et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol 2012;69:752-756.
31. Baumann M, Sahin K, Lechner C, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 2015;86:265-272.
32. Huppke P, Rostasy K, Karenfort M, et al. Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Mult Scler 2013; 19:941-946.
33. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelinoligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014;71:276-283.
34. Spadaro M, Gerdes LA, Mayer MC, et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol 2015;2:295-301.
35. Konig FB, Wildemann B, Nessler S, et al. Persistence of immunopathological and radiological traits in multiple sclerosis. Arch Neurol 2008;65:1527-1532.
36. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999;5:170-175.
37. Misu T, Hoftberger R, Fujihara K, et al. Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol 2013; 125:815-827.
38. Kezuka T, Usui Y, Yamakawa N, et al. Relationship between NMO-antibody and anti-MOG antibody in optic neuritis. J Neuroophthalmol 2012;32:107-110.
39. Aboulenein-Djamshidian F, Hoftberger R, Waters P, et al. Reduction in serum aquaporin-4 antibody titers during development of a tumor-like brain lesion in a patient with neuromyelitis optica: a serum antibody-consuming effect? J Neuropathol Exp Neurol 2015;74:194-197.
40. Martinez-Hernandez E, Sepulveda M, Rostasy K, et al. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor alpha1 subunit in patients with isolated optic neuritis. JAMA Neurol 2015; 72:187-193.